Children's Oncology Group

318 total trials 205 currently recruiting 66 completed

Trial Pipeline

RECRUITING Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

NCT06894979

RECRUITING Phase 1

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

NCT06620302

RECRUITING Phase 3

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330

RECRUITING Phase 3

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

NCT06647953

RECRUITING Phase 3

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06513962

RECRUITING Phase 1

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

NCT06247787

RECRUITING Phase 2

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

NCT06368817

RECRUITING Phase 2

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

NCT06410209

RECRUITING Phase 3

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

NCT05711667

RECRUITING

Somatic Mosaicism in Twins Discordant for Childhood Cancer

NCT06054295

RECRUITING

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

NCT05702645

RECRUITING

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

NCT05705531

RECRUITING Phase 3

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT05602194

RECRUITING

Molecular Epidemiology of Pediatric Germ Cell Tumors

NCT05564026

RECRUITING Phase 3

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

NCT05382338

RECRUITING Phase 2

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

NCT05504291

RECRUITING Phase 3

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585

RECRUITING Phase 3

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

NCT05235165

RECRUITING Phase 1

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT04870944

RECRUITING Phase 1

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119

RECRUITING

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

NCT05014165

RECRUITING Phase 2

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

NCT04684368

RECRUITING Phase 2

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318

RECRUITING Phase 3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562

RECRUITING Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085

RECRUITING Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916

RECRUITING Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

RECRUITING Phase 3

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

NCT03067181

RECRUITING

Project: Every Child for Younger Patients With Cancer

NCT02402244

RECRUITING

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

NCT01790152

RECRUITING

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

NCT00736749

ACTIVE NOT RECRUITING Phase 2

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

NCT06820957

ACTIVE NOT RECRUITING Phase 2

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171

ACTIVE NOT RECRUITING Phase 2

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

NCT04203316

ACTIVE NOT RECRUITING Phase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556

ACTIVE NOT RECRUITING

Vincristine Pharmacokinetics in Infants

NCT05359237

ACTIVE NOT RECRUITING Phase 1

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

NCT04903080

ACTIVE NOT RECRUITING Phase 1

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT04978727

ACTIVE NOT RECRUITING Phase 3

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597

ACTIVE NOT RECRUITING

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

NCT05228275

ACTIVE NOT RECRUITING

Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

NCT04928599

ACTIVE NOT RECRUITING Phase 3

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

NCT04994132

ACTIVE NOT RECRUITING

Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study

NCT05071859

ACTIVE NOT RECRUITING

Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE

NCT05020951

ACTIVE NOT RECRUITING Phase 2

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277

ACTIVE NOT RECRUITING Phase 3

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

NCT04089358

ACTIVE NOT RECRUITING Phase 2

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399

ACTIVE NOT RECRUITING Phase 1

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

NCT04258943

ACTIVE NOT RECRUITING

Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)

NCT04100408

ACTIVE NOT RECRUITING Phase 1

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

NCT04158739

ACTIVE NOT RECRUITING Phase 2

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398

ACTIVE NOT RECRUITING Phase 2

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

NCT03834961

ACTIVE NOT RECRUITING Phase 2

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT03794349

ACTIVE NOT RECRUITING Phase 3

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

NCT03533582

ACTIVE NOT RECRUITING Phase 3

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

NCT03057054

ACTIVE NOT RECRUITING Phase 3

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

NCT03223753

ACTIVE NOT RECRUITING Phase 2

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

NCT02724579

ACTIVE NOT RECRUITING

Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma

NCT03296371

ACTIVE NOT RECRUITING Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147

ACTIVE NOT RECRUITING

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

NCT03057626

ACTIVE NOT RECRUITING NA

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992

ACTIVE NOT RECRUITING Phase 3

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

NCT02521493

ACTIVE NOT RECRUITING Phase 3

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740

ACTIVE NOT RECRUITING Phase 3

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

NCT02176967

ACTIVE NOT RECRUITING NA

Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy

NCT01503086

ACTIVE NOT RECRUITING Phase 3

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

NCT01503632

ACTIVE NOT RECRUITING Phase 3

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

NCT01190930

ACTIVE NOT RECRUITING Phase 3

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

NCT01096368

ACTIVE NOT RECRUITING

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

NCT01117168

ACTIVE NOT RECRUITING Phase 3

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

NCT00945009

ACTIVE NOT RECRUITING

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

NCT00772200

ACTIVE NOT RECRUITING Phase 3

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

NCT00392327

ACTIVE NOT RECRUITING Phase 3

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

NCT00379340

ACTIVE NOT RECRUITING Phase 3

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

NCT00352534

ACTIVE NOT RECRUITING

Study of Kidney Tumors in Younger Patients

NCT00898365

ACTIVE NOT RECRUITING Phase 2

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

NCT00107198

ACTIVE NOT RECRUITING

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

NCT00082745

ACTIVE NOT RECRUITING

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

NCT00904241

COMPLETED Phase 1

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

NCT03320330

COMPLETED

Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

NCT03204916

COMPLETED

Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

NCT03206450

COMPLETED Phase 2

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

NCT02900976

COMPLETED Phase 1

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT02323880

COMPLETED Phase 1

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

NCT02097134

COMPLETED Phase 1

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

NCT02164838

COMPLETED Phase 2

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

NCT01824693

COMPLETED

Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas

NCT01802125

COMPLETED

Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

NCT01876303

COMPLETED

Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia

NCT01642121

COMPLETED

Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia

NCT01642069

COMPLETED Phase 2

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

NCT01602666

COMPLETED NA

Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents

NCT01556256

COMPLETED

Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial

NCT01407744

COMPLETED Phase 1

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356

COMPLETED

Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

NCT01496573

COMPLETED

Biomarkers in Samples From Younger Patients With Wilms Tumor

NCT01493817

COMPLETED Phase 3

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200

COMPLETED Phase 1

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

NCT01164163

COMPLETED

Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01807143

COMPLETED

Study of Blood Samples From Newborns With Down Syndrome

NCT00959283

What the Pipeline for Children's Oncology Group Shows

According to the ClinicalTrials.gov registry, Children's Oncology Group is linked to 318 US clinical trials across every stage of research activity. Of those, 205 studies are currently recruiting — about 64% of the sponsor's indexed portfolio — and 66 are already marked complete, representing roughly 21% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Children's Oncology Group reports 140 late-stage studies (Phase 3 and Phase 4 combined) and 133 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Children's Oncology Group is Leukemia with 12 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial